Advicenne Reports 2022 Sales Up 13% to €3.7 Million

Regulatory News:

Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces today 2022 sales of €3.7 million, up 13% compared to the previous year (2021: €3.3 million).

The 2022 growth is mainly driven by the sales of Sibnayal, growing 40% to €1.4 million (vs. €1 million in 2021). Sibnayal, a fixed dose combination of potassium citrate and potassium bicarbonate is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents, and children over 1 year of age.

The second half of 2022 saw a sharp acceleration in Sibnayal sales growth. The latter increased by 70% thanks to the launch in Great Britain by Advicenne’s team, the various partnerships concluded in Europe coming into force and the development of therapeutic management of patients suffering from dRTA in France. However, sales of Sibnayal are still mostly carried out under various European Early Access Programs providing early availability of the drug.

The Neurology franchise (Likozam and Ledvicen) remained stable at €2.3 million.

(€ million)	2022	2021	Growth
Sibnayal	1.39	0.99	+40%
Neurology	2.31	2.27	+1%
Total	3.69	3.38	+13%

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information see: https://advicenne.com/.

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets, and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005691/en/

The Advicenne Stock at the time of publication of the news with a raise of +0,72 % to 5,575EUR on Lang & Schwarz stock exchange (23. Januar 2023, 22:59 Uhr).